Lack of mRNA tech transfer “a blessing in disguise” for WHO vaccine team, says Afrigen boss

Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine

Get unlimited access to all IAM content